MX2020007665A - Terapia de combinacion para tratar o prevenir el cancer. - Google Patents

Terapia de combinacion para tratar o prevenir el cancer.

Info

Publication number
MX2020007665A
MX2020007665A MX2020007665A MX2020007665A MX2020007665A MX 2020007665 A MX2020007665 A MX 2020007665A MX 2020007665 A MX2020007665 A MX 2020007665A MX 2020007665 A MX2020007665 A MX 2020007665A MX 2020007665 A MX2020007665 A MX 2020007665A
Authority
MX
Mexico
Prior art keywords
treating
combination therapy
preventing cancer
cancer
preventing
Prior art date
Application number
MX2020007665A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808632.2A external-priority patent/GB201808632D0/en
Application filed by 4D Pharma Res Limited filed Critical 4D Pharma Res Limited
Publication of MX2020007665A publication Critical patent/MX2020007665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2020007665A 2018-01-19 2019-01-18 Terapia de combinacion para tratar o prevenir el cancer. MX2020007665A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808632.2A GB201808632D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer
PCT/GB2019/050144 WO2019141999A1 (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
MX2020007665A true MX2020007665A (es) 2020-09-14

Family

ID=65363308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007665A MX2020007665A (es) 2018-01-19 2019-01-18 Terapia de combinacion para tratar o prevenir el cancer.

Country Status (14)

Country Link
US (1) US20210060094A1 (he)
EP (1) EP3740221A1 (he)
JP (1) JP2021516661A (he)
KR (1) KR20200110343A (he)
CN (1) CN111902153A (he)
AU (1) AU2019210005A1 (he)
BR (1) BR112020014564A2 (he)
CA (1) CA3088343A1 (he)
IL (1) IL276073A (he)
MA (1) MA51621A (he)
MX (1) MX2020007665A (he)
SG (1) SG11202006874SA (he)
TW (1) TW201934138A (he)
WO (1) WO2019141999A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210101620A (ko) * 2020-02-10 2021-08-19 주식회사 천랩 패칼리박테리움 속 균주를 이용한 항암 치료
KR20230072316A (ko) * 2021-11-17 2023-05-24 씨제이바이오사이언스 주식회사 신규 류코노스톡 메센테로이데스 균주를 포함하는 암 또는 염증 예방 또는 치료용 조성물 및 이를 이용한 암 또는 염증의 예방 또는 치료 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US8187803B2 (en) * 2006-03-31 2012-05-29 Canon Kabushiki Kaisha Probe, probe set, probe-immobilized carrier, and genetic testing method
CN101595133B (zh) 2006-10-27 2012-11-14 比利时胶囊公司 羟丙基甲基纤维素硬胶囊及制备方法
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
AU2013371454B2 (en) * 2013-01-02 2019-01-03 Indaptus Therapeutics, Inc. Compositions and methods for treatment of cancer using bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
PE20180673A1 (es) * 2015-06-01 2018-04-19 Univ Chicago Tratamiento contra el cancer por manipulacion de la microflora comensal
GB201520497D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
CN119950689A (zh) * 2016-07-05 2025-05-09 北极星药业集团股份有限公司 使用精氨酸耗竭剂的组合癌症免疫疗法
EP3630942B1 (en) * 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain

Also Published As

Publication number Publication date
WO2019141999A1 (en) 2019-07-25
BR112020014564A2 (pt) 2020-12-08
EP3740221A1 (en) 2020-11-25
IL276073A (he) 2020-08-31
US20210060094A1 (en) 2021-03-04
AU2019210005A1 (en) 2020-08-06
MA51621A (fr) 2020-11-25
SG11202006874SA (en) 2020-08-28
JP2021516661A (ja) 2021-07-08
KR20200110343A (ko) 2020-09-23
CA3088343A1 (en) 2019-07-25
WO2019141999A8 (en) 2020-09-17
TW201934138A (zh) 2019-09-01
CN111902153A (zh) 2020-11-06

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MX2021003903A (es) Terapia combinada para el melanoma.
EA201991818A1 (ru) Лечение рака
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX383066B (es) Composiciones que comprenden cepas bacterianas.
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2020008195A (es) Compuestos para el tratamiento del dolor.
PH12021551949A1 (en) Cancer treatment
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007665A (es) Terapia de combinacion para tratar o prevenir el cancer.
PH12022550610A1 (en) Antibiotic combination therapies
EA202091636A1 (ru) Комбинированная терапия для лечения или профилактики рака
EA202091730A1 (ru) Комбинированная терапия для лечения или профилактики рака
EA202091635A1 (ru) Комбинированная терапия для лечения или профилактики рака
HK40039358A (en) Combination therapy for treating or preventing cancer
HK40039355A (en) Combination therapy for treating or preventing cancer
HK40039356A (en) Combination therapy for treating or preventing cancer
HK40039359A (en) Combination therapy for treating or preventing cancer
MX2021013776A (es) Composiciones que comprenden cepas bacterianas.
PH12021550101A1 (en) Cardio- and renosafe antidiabetic therapy
HK40080960A (en) Combination therapy for treating cancer
HK40054682A (en) Combination therapy for treating cancer